Novartis unit Sandoz AG has lost its bid to revoke Bayer’s patents for its top-selling blood clot drug Xarelto and has been barred from selling generic versions of the medication after a judge found the German pharma giant’s patents were valid.
Two more Victorian healthcare providers have been hit with a class action on behalf of junior doctors alleging they were not paid for unrostered work.
The digitisation of healthcare has left the industry particularly vulnerable to cyberattacks, and protecting consumers from breaches is one of the biggest challenges facing the sector, according to a new health law partner at Wotton + Kearney.
A judge has questioned a challenge by two class actions against Victorian aged care providers to a ruling that rejected their bid for insurance and financial information, which the defendants argue would have far-reaching implications.
Two cosmetic surgeons have filed defamation suits seeking aggravated damages over coverage by the ABC and Fairfax that allegedly painted them as “outlaw surgeons” who mutilated a patient and exploited the Medicare system.
Monash Health has won its challenge to a decision finding it wrongfully dismissed a librarian in a ‘sham’ redundancy.
An Australian law firm is investigating a class action against drug manufacturers over a commonly prescribed antibiotic said to cause “disabling” side effects, including nerve damage and psychosis.
Pathology giant Australian Clinical Labs has proposed a divestiture of collection centres amid competition concerns about its proposed takeover of competitor Healius, the owner of Dorevitch Pathology.
Monash IVF is gearing up for a legal privilege fight as it faces new claims about the team of senior doctors and directors working on a novel testing technique at the heart of a class action, including claims that one doctor “burnt paper evidence” from a trial of the technology.
Sanofi has lost its bid to limit evidence from experts for Amgen in a patent dispute over a cholesterol-lowering antibody, with a judge dismissing concerns about Amgen having a majority of experts giving concurrent evidence. In an application filed at the beginning of the month, the French pharmaceutical company sought to bar Amgen from relying…